🔍 Definition
Dementia is a clinical syndrome characterized by acquired, progressive deterioration in cognitive function — including memory, language, problem-solving, executive function, and behavior — severe enough to interfere with daily activities and social or occupational functioning. It is not a single disease but a clinical phenotype caused by multiple underlying pathological processes. Per ICD-10-CM FY2027 guidelines, dementia is coded using a structured hierarchy that captures etiology, severity, and documented behavioral or neuropsychiatric manifestations through the applicable code family and Tabular instructions.
The major subtypes encountered in clinical coding include: Alzheimer’s disease dementia (most common, ~60–70% of cases), vascular dementia (~15–20%), dementia with Lewy bodies (~5–10%), frontotemporal dementia (FTD/Pick’s disease) (~5–10%), and dementia due to other medical conditions (Parkinson’s disease, Huntington’s disease, HIV, TBI, Creutzfeldt-Jakob disease, and others). Accurate documentation and coding of the underlying etiology, severity level, and any behavioral or neuropsychiatric disturbances are essential for ICD-10-CM specificity and CMS-HCC v28 risk adjustment, including selection of the correct dementia severity HCC category (HCC 125, HCC 126, or HCC 127).
FY2023 ICD-10-CM introduced a major restructuring of dementia codes, adding a severity axis (mild/moderate/severe) and expanded behavioral disturbance 6th characters. These changes remain fully operative in FY2027. Every dementia encounter should capture: (1) etiology, (2) severity, and (3) behavioral/neuropsychiatric disturbances to maximize coding specificity and HCC RAF accuracy.
🗂️ Alternative Terminology
The following table identifies formal clinical and lay terminology used in documentation for dementia spectrum conditions. Coders must recognize all variants to ensure accurate code assignment.
| Formal / Clinical Name | Colloquial / Lay / Alternate Terms |
|---|---|
| Dementia due to Alzheimer’s disease | Alzheimer’s dementia; “Alzheimer’s”; ADRD; memory disease; senile dementia (older term) |
| Vascular dementia | Multi-infarct dementia; post-stroke dementia; arteriosclerotic dementia; vascular cognitive impairment (VCI) |
| Dementia with Lewy bodies (DLB) | Lewy body dementia; LBD; diffuse Lewy body disease |
| Frontotemporal dementia (FTD) | Pick’s disease; frontal lobe dementia; behavioral variant FTD (bvFTD); semantic dementia; progressive nonfluent aphasia (PPA) |
| Parkinson’s disease dementia | Parkinson’s dementia; PD-D; cognitive decline in Parkinson’s |
| Unspecified dementia | Senile dementia; organic brain syndrome; cognitive failure; “dementia NOS” |
| Mild cognitive impairment (MCI) | Early memory loss; pre-dementia; age-related memory impairment (ARMI); subjective cognitive decline |
| Dementia with behavioral disturbance | Agitated dementia; dementia with BPSD (behavioral and psychological symptoms of dementia) |
| Dementia with psychotic disturbance | Dementia with hallucinations; dementia with delusions; psychosis in dementia |
| Corticobasal degeneration | CBD; corticobasal syndrome (CBS) |
🩺 Signs & Symptoms
Clinical documentation should capture both cognitive and neuropsychiatric/behavioral features, as the latter directly affect ICD-10-CM code selection and HCC assignment.
Cognitive Symptoms
- Memory impairment: Episodic memory loss (recent > remote), difficulty learning new information, forgetting appointments, names, or recent events
- Language dysfunction: Word-finding difficulty, aphasia, reduced vocabulary, circumlocution
- Executive dysfunction: Impaired planning, sequencing, abstract reasoning, judgment
- Visuospatial impairment: Getting lost in familiar environments, difficulty with spatial tasks (Alzheimer’s, DLB)
- Attention/concentration deficits: Especially prominent in vascular and Lewy body dementia
Behavioral and Neuropsychiatric Symptoms (BPSD) — Code Triggers
- Agitation/aggression: Verbal or physical agitation, combativeness, resistiveness to care → agitation subcode “11” when documented; use “18” for other behavioral disturbance when supported by the specific dementia code family
- Psychotic disturbance: Visual/auditory hallucinations, paranoid delusions, misidentification syndromes → 6th character “2”
- Mood disturbance: Depression, emotional lability, apathy, dysphoria → 6th character “3”
- Anxiety disturbance: Generalized anxiety, sundowning, restlessness → 6th character “4”
- Sleep disturbance: REM sleep behavior disorder (especially DLB), insomnia, hypersomnia
- Wandering: Elopement behavior, getting lost
Neurological Signs by Subtype
- Alzheimer’s: Gradual onset, symmetric cortical atrophy; anosmia, myoclonus (late)
- Vascular: Stepwise decline, focal neurological deficits, history of stroke/TIA/hypertension
- Lewy body: Fluctuating cognition, visual hallucinations, parkinsonism, REM sleep behavior disorder (core features)
- FTD/Pick’s: Personality change, disinhibition, hyperorality, semantic/syntactic language loss
- Parkinson’s dementia: Motor features precede cognitive decline by ≥1 year
When documentation mentions agitation, combativeness, hallucinations, paranoid ideation, depression, anxiety, wandering, or sundowning in a patient with dementia — without the applicable disturbance-specific dementia code — a clarification query should be initiated. Capturing the behavioral/neuropsychiatric disturbance improves ICD-10-CM specificity and may affect the CMS-HCC v28 dementia tier depending on the code and documented severity; under V28, documented severity selects HCC 125 (severe), 126 (moderate), or 127 (mild or unspecified).
🧭 Differential Diagnosis
Coders and CDI specialists must be alert to conditions that may mimic or co-exist with dementia, as each has distinct code assignments and clinical implications.
| Condition | Key Distinguishing Features | ICD-10-CM Code(s) |
|---|---|---|
| Mild Cognitive Impairment (MCI) | Cognitive decline without functional impairment; does not meet dementia threshold | G31.84 |
| Age-related cognitive decline | Normal aging; no clinical impairment in daily function | R41.81 |
| Delirium (acute confusional state) | Acute onset, fluctuating, reversible; often superimposed on dementia | F05 (+ underlying cause) |
| Major depressive disorder with cognitive features (pseudodementia) | Mood disorder precedes cognitive symptoms; responds to antidepressants | F32.x / F33.x |
| Normal pressure hydrocephalus (NPH) | Triad: gait ataxia, urinary incontinence, cognitive decline; potentially reversible | G91.2 |
| Vitamin B12 deficiency encephalopathy | Reversible with B12 supplementation; megaloblastic anemia | E53.8, F09 |
| Thyroid-related cognitive decline (hypothyroidism) | Reversible with thyroid replacement therapy | E03.9, F09 |
| Amnestic disorder due to known physiological condition | Memory loss without other cognitive domains; not dementia | F04 |
| Corticobasal degeneration | Asymmetric apraxia, alien limb phenomenon, cortical sensory loss | G31.85 |
| Creutzfeldt-Jakob disease (CJD) | Rapidly progressive dementia, myoclonus, EEG changes; prion disease | A81.00–A81.09 + F02.8x |
📋 Clinical Indicators
The following table summarizes key documentation elements that support specific dementia code assignments. CDI specialists should audit for these indicators in every dementia encounter.
| Documentation Element | Code Impact | Why It Matters |
|---|---|---|
| Identified etiology (Alzheimer’s, vascular, Lewy body, FTD, Parkinson’s) | F01.xx / F02.8x / G30.x / G31.xx | Moves from F03.9x (unspecified) to specific etiology codes; dementia severity (mild/moderate/severe) drives V28 HCC 127/126/125 |
| Severity staging: mild / moderate / severe | A, B, C subcategory selection when documented; unspecified severity when not documented | Severity selection requires provider documentation and clinical judgment; do not infer severity from scores alone |
| Behavioral disturbance: agitation, aggression, combativeness | Agitation/other behavioral disturbance subcode selection; CMS-HCC v28 category depends on documented dementia severity | Captures clinically significant behavioral manifestation; in CMS-HCC v28, dementia maps by severity tier rather than by “with complications” vs. “without complication” |
| Psychotic disturbance: hallucinations, delusions | Psychotic disturbance subcode selection | Captures clinically significant neuropsychiatric manifestation; CMS-HCC v28 dementia category is severity-tiered, and concurrent psychiatric diagnoses require separate documentation when clinically present |
| Mood disturbance: depression, apathy, lability | Mood disturbance subcode selection | Treatment-relevant; may require antidepressant therapy; CMS-HCC v28 dementia category is severity-tiered, and distinct depressive disorders are reported separately when documented |
| Anxiety: anxiety, sundowning, restlessness | Anxiety subcode selection | Medication management and care plan implications; CMS-HCC v28 dementia category is severity-tiered rather than based on a “with complications” HCC |
| Alzheimer’s disease as underlying etiology | G30.x (PDx) + F02.8x (secondary) | Mandatory etiology/manifestation sequencing; G30.x PDx required |
| Vascular etiology documented | F01.5x (combination code) | F01.5x is a combination code — no separate cerebrovascular code needed |
| Lewy body disease documented | G31.83 + F02.8x | Must code both G31.83 and F02.8x per Tabular instructions |
| Parkinson’s disease with dementia | Appropriate G20.- code + applicable F02.- code | Parkinson’s disease/parkinsonism code sequenced first; dementia manifestation code sequenced second per etiology/manifestation convention |
| CDR (Clinical Dementia Rating) or MMSE/MoCA score documented | Supports severity axis selection | CDR 0.5–1 = mild; CDR 2 = moderate; CDR 3 = severe |
| Cognitive assessment services (99483) | Supports annual Medicare billing | Annual cognitive assessment and care plan (ACP); HCC documentation opportunity |
Do not code F03.9x (unspecified dementia) when the etiology is documented. “Dementia” without further specification may default to F03.9x, but if the record contains documentation of Alzheimer’s disease, vascular disease, Lewy body disease, or another identified cause, the specific combination code set must be used. Unspecified dementia codes are also MEAT-challenged in risk adjustment audits — payers frequently query or deny dementia HCCs when only F03.9x appears without supporting clinical documentation of the underlying cause.
🦴 Anatomy & Pathophysiology
Understanding the pathophysiological basis of dementia subtypes helps coders and CDI specialists identify documentation clues that support specific code selection.
Alzheimer’s Disease
Alzheimer’s disease (AD) is characterized by extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. Neurodegeneration begins in the entorhinal cortex and hippocampus (explaining early episodic memory loss) before spreading to association cortices. The 2026 Alzheimer’s Association Facts and Figures report estimates that 7.4 million Americans age 65 and older are living with Alzheimer’s in 2026. The 2023 FDA approvals of lecanemab (Leqembi) and 2024 approval of donanemab (Kisunla) — both anti-amyloid monoclonal antibodies — represent the first disease-modifying therapies for early AD, targeting Aβ clearance.
Vascular Dementia
Vascular cognitive impairment arises from cerebrovascular disease — including large-vessel strokes, small-vessel (lacunar) disease, and white matter hyperintensities. The mechanism involves ischemic injury to cortical and subcortical networks essential for cognition, particularly frontal-subcortical circuits. Risk factors (hypertension, diabetes, atrial fibrillation, dyslipidemia) are the same as for stroke. Unlike Alzheimer’s, vascular dementia often presents with stepwise decline rather than gradual progression.
Lewy Body Dementia
Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) share the pathological substrate of alpha-synuclein aggregates (Lewy bodies) distributed in cortical and limbic regions. DLB is distinguished by dementia onset concurrent with or preceding motor features; in PDD, motor symptoms precede cognitive decline by ≥1 year. The characteristic fluctuating cognition and visual hallucinations result from cholinergic deficits and limbic involvement. REM sleep behavior disorder (RBD) is an early biomarker. ICD-10-CM uses G31.83 for Lewy body disease, coded with F02.8x for the dementia manifestation.
Frontotemporal Dementia (FTD / Pick’s Disease)
FTD encompasses a heterogeneous group of neurodegenerative disorders with selective frontal and temporal lobe atrophy. Pathologically, FTD is associated with tau (Pick bodies in Pick’s disease; MAPT mutations), TDP-43, or FUS protein inclusions. The behavioral variant (bvFTD) presents with personality change, disinhibition, and executive dysfunction; language variants present as progressive aphasia. G31.01 (Pick’s disease) and G31.09 (other FTD) are coded with F02.8x for the dementia manifestation.
Severity Staging Correlates
The FY2027 severity subcategories (A = mild, B = moderate, C = severe) align clinically with validated staging tools such as Alzheimer’s Association staging, CDR (Clinical Dementia Rating scale), and FAST (Functional Assessment Staging Test), but severity code assignment requires provider documentation. CDR 0.5–1 corresponds to mild; CDR 2 to moderate; CDR 3 to severe. Documentation of specific CDR, MMSE, or MoCA scores supports severity axis assignment and defends against retrospective audit challenges.
💊 Medication Impact / Treatment
Pharmacological and non-pharmacological management of dementia directly informs code selection, CDI queries, and HCPCS/CPT billing opportunities.
Cholinesterase Inhibitors (AChEIs)
First-line symptomatic therapy for mild-to-moderate Alzheimer’s dementia includes donepezil (Aricept — all stages), rivastigmine (Exelon — also for PDD), and galantamine (Razadyne). These agents inhibit acetylcholinesterase, increasing synaptic acetylcholine. All are oral medications billed under Part D via NDC; rivastigmine transdermal patch (HCPCS J3490) may be billed under Part B in select circumstances. Presence of AChEI prescriptions in the medication list is a strong CDI indicator that the clinician has diagnosed and is treating dementia.
NMDA Receptor Antagonist
Memantine (Namenda) is approved for moderate-to-severe Alzheimer’s dementia; it may be combined with an AChEI. Memantine is also used off-label in other dementia subtypes. Documentation of memantine use supports severity coding (moderate/severe subcategory — B or C).
Disease-Modifying Anti-Amyloid Therapies (Early AD)
- Lecanemab (Leqembi) — FDA-approved January 2023 (accelerated) and July 2023 (traditional approval) for early AD (MCI due to AD or mild AD dementia with confirmed amyloid pathology). HCPCS J0174 describes lecanemab-irmb for intravenous injection, 1 mg; do not use J0173 for Leqembi. Billed for IV infusion when reported under Part B coverage and payer policy.
- Donanemab (Kisunla) — FDA-approved July 2024 for early symptomatic AD. HCPCS J0175 describes injection, donanemab-azbt, 2 mg (Kisunla); unclassified codes are reserved for FDA-approved anti-amyloid therapies covered under NCD 200.3 that do not yet have a dedicated HCPCS code. IV infusion; requires amyloid confirmation.
Behavioral/Neuropsychiatric Symptom Management
- Antipsychotics (quetiapine, risperidone, olanzapine — all off-label): for agitation, psychosis; FDA black box warning for use in elderly with dementia (increased mortality risk)
- Antidepressants (SSRIs — sertraline, citalopram; SNRIs): for mood disturbance, anxiety, apathy
- Benzodiazepines (short-term only): for acute agitation; risk of falls, paradoxical agitation
- Melatonin / trazodone: for sleep-wake cycle disturbances
- Pimavanserin (Nuplazid): FDA-approved for Parkinson’s disease psychosis; investigational for dementia-related psychosis (DRP)
Non-Pharmacological Interventions
Cognitive stimulation therapy, structured activity programs, caregiver training, and environmental modifications are mainstays of dementia care. Music therapy, reminiscence therapy, and sensory stimulation are evidence-based non-drug approaches for BPSD management per Alzheimer’s Association treatment guidelines.
Preview ends here. The full guide continues with FY2027 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 ICD-10-CM Guidelines
Etiology/Manifestation Convention — Critical Sequencing Rules
The ICD-10-CM Official Guidelines for Coding and Reporting FY2027 (Section I.C.5.d and Tabular instructions) provide the following documentation and sequencing rules for dementia:
- Alzheimer’s disease with dementia: Assign G30.x (Alzheimer’s disease) as the principal/first-listed diagnosis, followed by F02.8x (dementia in Alzheimer’s) as an additional code. The Tabular note at G30 states “Use additional code to identify: dementia with behavioral disturbance (F02.8x).” The note at F02.8x states “Code first the underlying physiological condition.” This is the etiology/manifestation convention — do NOT reverse the order.
- Vascular dementia (F01.5x): F01.5x codes are combination codes that include both the vascular etiology and the dementia. No separate cerebrovascular disease code is required unless a distinct acute stroke or other condition is present. F01.5x is sequenced as appropriate based on the reason for the encounter.
- Lewy body disease (G31.83): Code G31.83 first (Lewy body dementia / dementia with Lewy bodies), then F02.8x as an additional code. Per Tabular note at G31.83: “Use additional code for associated symptoms” including dementia.
- Parkinson’s disease with dementia: Code the appropriate G20.- Parkinson’s disease/parkinsonism code first, followed by the applicable F02.- dementia manifestation code. Do NOT assume dementia is present in every Parkinson’s patient — it must be explicitly documented.
- FTD/Pick’s disease: Code G31.01 (Pick’s disease) or G31.09 (other FTD) first, then F02.8x as an additional code.
- Dementia without identified etiology: Use F03.9x (unspecified dementia) when no underlying cause is documented. CDI should query for etiology before defaulting to F03.9x.
- Huntington’s disease: Code G10 (Huntington’s disease) first, then F02.8x.
- CJD with dementia: Code prion disease (A81.0x) first, then F02.8x.
- HIV with dementia: B20 (HIV disease) first, then F02.8x.
Severity and Behavioral Disturbance Axis (FY2023+ — Operative FY2026)
Effective FY2023, dementia codes include a severity axis and expanded behavioral disturbance 6th character. This structure applies to F01.5x, F02.8x, and F03.9x code families:
- 5th character (severity): 9 = unspecified severity; A = mild; B = moderate; C = severe
- 6th character (behavioral/neuropsychiatric disturbance):
- 0 = without behavioral disturbance, psychotic symptoms, mood disturbance, or anxiety
- 1 = with behavioral disturbance (non-specific agitation/behavioral symptoms)
- 2 = with psychotic disturbance (hallucinations, delusions)
- 3 = with mood disturbance (depression, lability, apathy)
- 4 = with anxiety disturbance
- 11 = with agitation (specific 7-character subcategory where applicable)
The highest level of specificity should always be coded. If multiple behavioral disturbances are present (e.g., both psychotic features and agitation), code the one that best reflects the predominant clinical presentation or that the provider specifically documents. Per CMS/NCHS ICD-10-CM Tabular, only one behavioral disturbance 6th character may be assigned per dementia code.
Coding Clinic Guidance on Severity Documentation
Severity must be clinically documented by the treating provider — coders may not infer severity from functional assessment scores alone without physician attestation. When severity is not specified, assign the “unspecified” (9) severity subcategory (e.g., F03.90). Query the provider when documented clinical findings (CDR score, MMSE/MoCA, functional status) suggest a severity level that is not explicitly stated. See the AHA Coding Clinic section below for specific guidance citations.
Etiology/manifestation sequencing is a top audit target. Reversing the order (coding F02.8x first, then G30.x) is incorrect and will trigger claim edits. For Alzheimer’s-related dementia, G30.x MUST be the first-listed or principal diagnosis. Similarly, coding G31.83 or G20 without the corresponding F02.8x (when dementia is documented) results in incomplete capture and potential HCC gap. Both codes in the pair must appear on the claim.
🔢 ICD-10-CM Code Set (Tabular)
Alzheimer’s Disease (Code First — G30.x)
| Code | Description | Notes / Pairing |
|---|---|---|
| G30.0 | Alzheimer’s disease with early onset | Onset before age 65; code first, then F02.8x for dementia |
| G30.1 | Alzheimer’s disease with late onset | Onset age 65+; most common; code first, then F02.8x |
| G30.8 | Other Alzheimer’s disease | Atypical or mixed presentations |
| G30.9 | Alzheimer’s disease, unspecified | When onset not specified; query for onset type |
Vascular Dementia (F01.5x — Combination Codes)
| Code | Description | Notes |
|---|---|---|
| F01.50 | Vascular dementia, unspecified severity, without behavioral disturbance | Baseline vascular dementia; no behavioral features documented |
| F01.511 | Vascular dementia, unspecified severity, with agitation | Specific agitation subcode; 7 characters |
| F01.518 | Vascular dementia, unspecified severity, with other behavioral disturbance | Other behavioral (not agitation) |
| F01.52 | Vascular dementia, unspecified severity, with psychotic disturbance | Hallucinations, delusions |
| F01.53 | Vascular dementia, unspecified severity, with mood disturbance | Depression, lability, apathy |
| F01.54 | Vascular dementia, unspecified severity, with anxiety disturbance | Anxiety, sundowning |
| F01.A0 | Vascular dementia, mild, without behavioral disturbance | Mild severity; A = mild severity subcategory |
| F01.A11 | Vascular dementia, mild, with agitation | Mild + agitation |
| F01.A18 | Vascular dementia, mild, with other behavioral disturbance | Mild + other behavioral disturbance |
| F01.A2 | Vascular dementia, mild, with psychotic disturbance | Mild + psychotic features |
| F01.A3 | Vascular dementia, mild, with mood disturbance | Mild + mood disturbance |
| F01.A4 | Vascular dementia, mild, with anxiety disturbance | Mild + anxiety |
| F01.B0 | Vascular dementia, moderate, without behavioral disturbance | B = moderate severity |
| F01.B11 | Vascular dementia, moderate, with agitation | Moderate + agitation |
| F01.B18 | Vascular dementia, moderate, with other behavioral disturbance | Moderate + other behavioral disturbance |
| F01.B2 | Vascular dementia, moderate, with psychotic disturbance | Moderate + psychosis |
| F01.B3 | Vascular dementia, moderate, with mood disturbance | Moderate + mood |
| F01.B4 | Vascular dementia, moderate, with anxiety disturbance | Moderate + anxiety |
| F01.C0 | Vascular dementia, severe, without behavioral disturbance | C = severe severity |
| F01.C11 | Vascular dementia, severe, with agitation | Severe + agitation |
| F01.C18 | Vascular dementia, severe, with other behavioral disturbance | Severe + other behavioral disturbance |
| F01.C2 | Vascular dementia, severe, with psychotic disturbance | Severe + psychosis |
| F01.C3 | Vascular dementia, severe, with mood disturbance | Severe + mood |
| F01.C4 | Vascular dementia, severe, with anxiety disturbance | Severe + anxiety |
Dementia in Diseases Classified Elsewhere (F02.8x — Manifestation Code)
| Code | Description | Etiology (Code First) |
|---|---|---|
| F02.80 | Dementia in other diseases, unspecified severity, without behavioral disturbance | G30.x, G31.83, G31.01, G31.09, G20, G10, A81.0x, B20, etc. |
| F02.811 | Dementia in other diseases, unspecified severity, with agitation | Same etiology codes apply |
| F02.818 | Dementia in other diseases, unspecified severity, with other behavioral disturbance | Non-agitation behavioral |
| F02.82 | Dementia in other diseases, unspecified severity, with psychotic disturbance | Hallucinations/delusions common in DLB, AD |
| F02.83 | Dementia in other diseases, unspecified severity, with mood disturbance | Depression, apathy |
| F02.84 | Dementia in other diseases, unspecified severity, with anxiety disturbance | Anxiety, sundowning |
| F02.A0 | Dementia in other diseases, mild, without behavioral disturbance | Mild severity (CDR 1 / MMSE 20–26) |
| F02.A11 | Dementia in other diseases classified elsewhere, mild, with agitation | Mild + agitation |
| F02.A18 | Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance | Mild + other behavioral disturbance |
| F02.A2 | Dementia in other diseases, mild, with psychotic disturbance | Mild + psychosis → HCC 127 |
| F02.A3 | Dementia in other diseases, mild, with mood disturbance | Mild + mood → HCC 127 |
| F02.A4 | Dementia in other diseases, mild, with anxiety disturbance | Mild + anxiety → HCC 127 |
| F02.B0 | Dementia in other diseases, moderate, without behavioral disturbance | Moderate severity (CDR 2 / MMSE 10–19) |
| F02.B11 | Dementia in other diseases, moderate, with agitation | Moderate + agitation → HCC 126 |
| F02.B2 | Dementia in other diseases, moderate, with psychotic disturbance | Moderate + psychosis |
| F02.B3 | Dementia in other diseases, moderate, with mood disturbance | Moderate + mood |
| F02.B4 | Dementia in other diseases, moderate, with anxiety disturbance | Moderate + anxiety |
| F02.C0 | Dementia in other diseases, severe, without behavioral disturbance | Severe (CDR 3 / MMSE <10) |
| F02.C11 | Dementia in other diseases, severe, with agitation | Severe + agitation → HCC 125 |
| F02.C2 | Dementia in other diseases, severe, with psychotic disturbance | Severe + psychosis |
| F02.C3 | Dementia in other diseases, severe, with mood disturbance | Severe + mood |
| F02.C4 | Dementia in other diseases, severe, with anxiety disturbance | Severe + anxiety |
Unspecified Dementia (F03.9x)
| Code | Description | Notes |
|---|---|---|
| F03.90 | Unspecified dementia, unspecified severity, without behavioral disturbance | Last resort when no etiology documented; query first |
| F03.911 | Unspecified dementia, unspecified severity, with agitation | Behavioral disturbance captured even when etiology unspecified |
| F03.918 | Unspecified dementia, unspecified severity, with other behavioral disturbance | |
| F03.92 | Unspecified dementia, unspecified severity, with psychotic disturbance | |
| F03.93 | Unspecified dementia, unspecified severity, with mood disturbance | |
| F03.94 | Unspecified dementia, unspecified severity, with anxiety disturbance | |
| F03.A0 | Unspecified dementia, mild, without behavioral disturbance | Mild unspecified |
| F03.A11 | Unspecified dementia, mild, with agitation | |
| F03.A18 | Unspecified dementia, mild, with other behavioral disturbance | |
| F03.B0 | Unspecified dementia, moderate, without behavioral disturbance | Moderate unspecified |
| F03.B11 | Unspecified dementia, moderate, with agitation | |
| F03.C0 | Unspecified dementia, severe, without behavioral disturbance | Severe unspecified |
| F03.C11 | Unspecified dementia, severe, with agitation |
Related Degenerative and Neurological Codes
| Code | Description | Notes |
|---|---|---|
| G31.01 | Pick’s disease | Code first; then F02.8x for dementia manifestation |
| G31.09 | Other frontotemporal dementia | bvFTD variants excluding Pick’s; code first + F02.8x |
| G31.83 | Neurocognitive disorder with Lewy bodies | Code first when Lewy body disease/neurocognitive disorder is the etiology; assign the applicable F02.- dementia manifestation code when dementia is documented |
| G31.84 | Mild cognitive impairment of uncertain or unknown etiology | NOT dementia; no HCC mapping; documents at-risk status; if a known physiological etiology is documented, verify whether F06.7- is more appropriate |
| G31.85 | Corticobasal degeneration | Code first; dementia with F02.8x if documented |
| G31.1 | Senile degeneration of brain, not elsewhere classified | Rarely used; query for more specific etiology |
| G20.- | Parkinson’s disease/parkinsonism — select the most specific code (e.g., G20.A1, G20.A2, G20.B1, G20.B2, or G20.C when supported) | Code first when Parkinson’s-related dementia is documented; then assign the applicable F02.- dementia manifestation code |
| G10 | Huntington’s disease | Code first + F02.8x for dementia manifestation |
| F04 | Amnestic disorder due to known physiological condition | Memory loss only; NOT dementia; distinct from F02.8x |
| R41.81 | Age-related cognitive decline | Not MCI; normal aging; no HCC |
| R41.82 | Altered mental status, unspecified | Symptom code; query for underlying cause; not for chronic dementia |
| Z86.59 | Personal history of other mental and behavioral disorders | May be used for resolved/historical dementia when appropriate; verify payer and encounter context because Z86.59 is a nonspecific Z code |
🔎 Indexing
The following ICD-10-CM Alphabetic Index pathways guide coders to correct code selection. Always verify in the Tabular List and confirm with FY2027 code tables.
| Index Entry / Provider Documentation | Index Path | Code(s) |
|---|---|---|
| “Dementia, Alzheimer’s type” or “Alzheimer’s dementia” | Dementia → in (due to) → Alzheimer’s disease → early/late onset | G30.0–G30.9 + F02.8x |
| “Vascular dementia” | Dementia → vascular → [severity] → [behavioral modifier] | F01.50–F01.C11 |
| “Dementia with Lewy bodies” or “Lewy body dementia” | Dementia → Lewy body; also Lewy body → dementia | G31.83 + F02.8x |
| “Pick’s disease” or “frontotemporal dementia” | Pick’s disease → G31.01; Disease, Pick’s; Dementia → in → Pick’s disease | G31.01 or G31.09 + F02.8x |
| “Dementia, Parkinson’s” or “Parkinson’s disease with dementia” | Dementia → in (due to) → Parkinson’s disease; appropriate G20.- code + applicable F02.- code | G20.- + F02.- |
| “Dementia with agitation” | Dementia → [type] → with behavioral disturbance → agitation | Appropriate Fxx.x11 code |
| “Dementia with hallucinations” / “psychotic features” | Dementia → [type] → with psychotic disturbance | Appropriate Fxx.x2 code |
| “Senile dementia” (non-Alzheimer) | Dementia → senile → F03.90 (verify provider intent) | F03.90 or query etiology |
| “Mild cognitive impairment” | Impairment, cognitive, mild → G31.84 | G31.84 |
| “Amnestic disorder, organic” | Disorder, amnestic → F04 | F04 |
🏥 CPT
The following CPT codes are commonly used in the evaluation, diagnosis, and cognitive assessment of dementia patients.
| CPT Code | Description | Global | Notes |
|---|---|---|---|
| 99483 | Cognitive assessment and care plan services for a patient with signs and/or symptoms of cognitive impairment | N/A (E/M) | Requires the required cognitive assessment/care-plan elements, including caregiver/independent historian involvement when applicable and a written care plan; typically 50 minutes face-to-face, but CPT 2027 states 99483 has no required time threshold; a single physician or QHP should not report 99483 more than once every 180 days |
| 96116 | Neurobehavioral status exam (clinical assessment of thinking, reasoning, and judgment), first hour | XXX | Physician/QHP face-to-face; initial comprehensive cognitive assessment; typically billed same visit as 99483 or separately; often used for new dementia diagnosis workup |
| 96121 | Neurobehavioral status exam, each additional hour | ZZZ (add-on) | Add-on to 96116; billed per additional hour of face-to-face assessment |
| 96132 | Neuropsychological testing evaluation services, first hour | XXX | Physician/QHP interpretation of neuropsychological test battery; first hour; typically for complex or uncertain diagnoses (early-onset dementia, FTD vs. AD differential) |
| 96133 | Neuropsychological testing evaluation services, each additional hour | ZZZ (add-on) | Add-on to 96132 |
| 96136 | Psychological or neuropsychological test administration and scoring, first 30 minutes | XXX | Test administration (not evaluation); may be billed by technician under supervision; first 30 min |
| 96137 | Psychological or neuropsychological test administration and scoring, each additional 30 minutes | ZZZ (add-on) | Add-on to 96136 |
| 70553 | MRI brain, without and with contrast | XXX | Standard structural brain MRI for dementia workup; identifies atrophy patterns, white matter disease, vascular lesions, hippocampal volume loss; ACR Appropriateness Criteria recommends for initial dementia evaluation |
| 70551 | MRI brain, without contrast | XXX | May be sufficient for initial workup; often preferred for serial monitoring |
| 78608 | PET brain imaging; metabolic evaluation | XXX | FDG-PET; identifies hypometabolism patterns characteristic of AD (temporoparietal) vs. FTD (frontal); Medicare covers for differential diagnosis of AD vs. FTD in select circumstances per CMS NCA |
| 78811 / 78814 | PET or PET/CT, limited area (e.g., head/neck) | XXX | Amyloid PET brain imaging is typically reported with limited-area PET (78811) or limited-area PET/CT (78814), along with the applicable radiopharmaceutical HCPCS code; verify payer coverage and registry/CED requirements for anti-amyloid monoclonal antibody treatment |
| 86235 | Antinuclear antibody (ANA); cell-specific | N/A (lab) | Part of autoimmune encephalopathy workup when dementia differential is broad |
CPT 99483 (Cognitive Assessment & Care Plan) is a Medicare-covered separate cognitive assessment visit. A single physician or qualified health care professional should not report 99483 more than once every 180 days. Documentation must support all required elements and a written care plan; if required elements are not performed or are deemed unnecessary, report the appropriate E/M code instead. Check payer/NCCI rules before reporting 99483 with other same-date services.
- 99483: 2026 descriptor used the longer “Assessment of and care planning for a patient with cognitive impairment…” language with required element/time wording; CPT 2027 descriptor is “Cognitive assessment and care plan services for a patient with signs and/or symptoms of cognitive impairment.”
🧾 HCPCS
| HCPCS Code | Description | Typical Use / Notes |
|---|---|---|
| J0174 | Lecanemab-irmb, for intravenous injection, 1 mg (Leqembi) | Anti-amyloid monoclonal antibody for early AD; IV infusion; requires amyloid confirmation; billed per mg; FDA full approval July 2023; Medicare coverage under Part B in applicable hospital outpatient/physician office settings per CMS coverage rules. Do not use J0173 for lecanemab. |
| J0175 | Injection, donanemab-azbt, 2 mg (Kisunla) | Anti-amyloid monoclonal antibody for early symptomatic AD; IV infusion; requires amyloid confirmation; billed per 2 mg unit. Use J3490 only for unclassified drugs when no product-specific HCPCS code applies; always document drug name, dose, route, and units. |
| G0136 | Administration of a standardized, evidence-based Social Determinants of Health (SDOH) Risk Assessment tool | Frequently co-billed at dementia care visits; caregiver burden screening; relevant to care planning for dementia patients |
| G0177 | Training and educational services, per session | Caregiver education for dementia management in home health settings |
| G0317 | Prolonged Nursing Facility E&M beyond 45 minutes | Applicable for complex dementia management in SNF/NF settings requiring extended time |
| G0318 | Prolonged Home/Domiciliary E&M beyond 60 minutes | Complex dementia home visits exceeding time thresholds |
| Q9982 | Florbetapir F18 injection, diagnostic (Amyvid) — amyloid PET | Amyloid PET agent; required for lecanemab/donanemab eligibility confirmation; billed per mCi |
| Q9988 | Flortaucipir F18 injection (Tauvid) — tau PET | Tau PET imaging for Alzheimer’s disease confirmation in complex cases; Medicare NCA coverage |
Note on oral cholinesterase inhibitors (donepezil, galantamine, rivastigmine oral/patch): These are typically covered under Medicare Part D and billed via NDC through the pharmacy benefit. They do not have separately billable HCPCS J-codes under Part B in standard outpatient settings except in specific circumstances (e.g., rivastigmine patch in select DME/home health contexts). Coders should document medication reconciliation to support MEAT criteria for HCC coding purposes.
📚 AHA Coding Clinic
| Coding Clinic Reference | Topic / Guidance Summary |
|---|---|
| AHA Coding Clinic, 4Q 2022, “Dementia: Stage of Severity, Behavioral and Physical Symptoms” | FY 2023 Dementia Code Expansion: Effective October 1, 2022, new subcategories under F01, F02, and F03 identify the stage of severity (mild, moderate, severe) and the behavioral and psychological symptoms of dementia, such as agitation, psychotic disturbance, mood disturbance, and anxiety. In Coding Clinic’s example, severe dementia due to late-onset Alzheimer’s disease with agitation and combativeness is coded G30.1 and F02.C11. Selection of the severity level requires the provider’s clinical judgment and is based on provider documentation; if severity is not documented, assign the code for unspecified severity (Official Guidelines FY 2027, Section I.C.5.d). |
| Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Tabular List of Diseases and Injuries FY 2027, category F01 | Vascular Dementia Coding: Category F01, Vascular dementia, includes vascular dementia as a result of infarction of the brain due to vascular disease (including hypertensive cerebrovascular disease), arteriosclerotic dementia, and multi-infarct dementia. The Tabular instructs to code first, if applicable, any causal condition. Subcategories F01.5-, F01.A-, F01.B-, and F01.C- identify unspecified, mild, moderate, and severe severity, with further characters for behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety. |
| AHA Coding Clinic, 1Q 2017, “Alzheimer’s Disease and Dementia” | Alzheimer’s Disease Etiology/Manifestation Convention: Dementia is an inherent part of Alzheimer’s disease, so the provider does not need to document dementia separately. Code G30.- represents the underlying etiology and must be sequenced first, followed by the F02.- manifestation code (Official Guidelines Section I.A.13); Coding Clinic assigned G30.9 followed by F02.80. F02.81, also cited in that article, was expanded October 1, 2022 (FY 2023) and is no longer a valid code; use F02.811 or F02.818, or the severity-specific F02.A-, F02.B-, and F02.C- codes. |
| AHA Coding Clinic, 4Q 2016, “Lewy Body Dementia”; AHA Coding Clinic, 2Q 2017, “Parkinson’s Dementia versus Parkinsonism” | Lewy Body and Parkinson’s Dementia: Lewy body dementia is coded G31.83 with F02.80 when no behavioral disturbance is documented (4Q 2016). In FY 2027, G31.83 is titled Neurocognitive disorder with Lewy bodies and lists Lewy body dementia as an inclusion term. Dementia due to Parkinson’s disease with aggressive behavior was coded G20 and F02.81 (2Q 2017); both codes have since been expanded, so assign the appropriate G20.- code (G20.A1-G20.B2) and the appropriate F02.- code for severity and behavior. |
| Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.B.14 | Behavioral Disturbance Capture: Behavioral and psychological symptoms of dementia (such as agitation, psychotic disturbance, mood disturbance, and anxiety) are captured with the characters following the severity level in categories F01, F02, and F03. Code assignment is based on the documentation of the patient’s provider; behavioral symptoms of dementia are not among the items in Section I.B.14 (such as BMI, pressure ulcer stage, and laterality) that may be taken from other clinicians’ documentation. If there is conflicting medical record documentation, query the patient’s provider. |
AHA Coding Clinic advice applies from its effective date and may be superseded by later advice or code-set changes. Before applying any reference above, confirm current guidance through a subscription to AHA Coding Clinic, available from the AHA Central Office. The conventions and instructions of the classification take precedence over the guidelines, and adherence to the ICD-10-CM Official Guidelines for Coding and Reporting is required under HIPAA (ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I).
💰 HCC / Risk Adjustment
Dementia HCCs in V28 are set by documented severity, not by behavioral disturbance. Mappings below follow the 2024 CMS-HCC model (commonly called V28), which CMS uses at 100 percent for non-PACE Medicare Advantage risk scores and continued for CY 2027, and the CMS 2027 Initial ICD-10-CM Mappings. Coefficients vary by enrollee segment and payer, so this guide does not quote RAF weights; check the current CMS model software. Hierarchies are applied by CMS after coding: code every documented, supported condition.
| ICD-10-CM Code(s) | Description | V28 HCC | Coding / Documentation Notes |
|---|---|---|---|
| F01.C-, F02.C-, F03.C- | Vascular, other-disease, or unspecified dementia, severe (with or without disturbance) | HCC 125 — Dementia, Severe | Drops HCCs 126 and 127 |
| F01.B-, F02.B-, F03.B- | Dementia, moderate | HCC 126 — Dementia, Moderate | Drops HCC 127 |
| F01.5-, F01.A-, F02.8-, F02.A-, F03.9-, F03.A- | Dementia, unspecified severity or mild | HCC 127 — Dementia, Mild or Unspecified | Behavioral, psychotic, mood, or anxiety disturbance codes stay in the same severity HCC |
| G30.-, G31.01, G31.09, G31.83 | Alzheimer’s disease; frontotemporal dementia; dementia with Lewy bodies | HCC 127 | Code also the F02 dementia code with its severity (Tabular note) |
| G31.84, R41.81 | Mild cognitive impairment; age-related cognitive decline | No V28 payment HCC | Not dementia |
| F05 | Delirium due to known physiological condition | No V28 payment HCC | Code the underlying condition |
Severity is a provider judgment; if the documentation does not state severity, assign the unspecified-severity code (Guideline I.C.5.d). V24 HCCs 51 and 52 (dementia with and without complication) no longer apply.
Do not infer moderate or severe dementia from functional scores, nursing notes, or medication lists. When the record supports a severity the provider has not stated, use a compliant, non-leading query.
Sources: CMS 2027 Initial ICD-10-CM Mappings (2024 CMS-HCC model, V28); CMS CY 2024 Rate Announcement, Attachment VI (hierarchies, interactions); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines. Verified November 3, 2026.
✍️ CDI Query Templates
All queries below follow AHIMA/ACDIS compliant format: non-leading, multiple-choice, clinically grounded. Queries should be accompanied by supporting clinical findings from the medical record.
| Scenario | Query Wording (Non-Leading, Multiple Choice) |
|---|---|
| Dementia documented without etiology (F03.9x assigned) | Clinical context: Patient presents with progressive cognitive decline affecting daily activities. No specific etiology for dementia is identified in the current documentation. Based on your clinical evaluation, is it appropriate to specify an underlying etiology for this patient’s dementia? Please indicate:
|
| Dementia coded without severity (Fxx.90 or Fxx.80 assigned) | Clinical context: This patient carries a diagnosis of [Alzheimer’s/vascular/unspecified] dementia. No severity level is specified in the current documentation. Clinical findings include [MMSE score X / CDR score X / functional assessment findings]. Would it be clinically appropriate to specify the severity of this patient’s dementia? Please indicate:
|
| Dementia coded without behavioral/neuropsychiatric disturbance but chart contains documentation of agitation, hallucinations, depression, or anxiety | Clinical context: The medical record contains documentation of [agitation/combativeness/visual hallucinations/paranoid ideation/depressive symptoms/anxiety] in the context of this patient’s known dementia diagnosis (per [nursing notes/behavioral assessment/medication orders for antipsychotic/antidepressant dated X]). Do any of the following behavioral or neuropsychiatric disturbances represent a clinically significant manifestation of this patient’s dementia? Please indicate:
|
| Patient on lecanemab or donanemab — ensure diagnosis is early AD (mild) and correctly coded | Clinical context: Patient is receiving anti-amyloid immunotherapy (lecanemab/donanemab) for Alzheimer’s disease. These therapies are indicated only for early symptomatic Alzheimer’s disease with confirmed amyloid pathology. To support accurate diagnosis coding, can you confirm:
|
| MCI documented — query for dementia progression | Clinical context: Patient has a prior diagnosis of mild cognitive impairment (MCI, G31.84). Current documentation indicates [new functional impairment / caregiver reports difficulties with ADLs / cognitive decline per formal testing / medication management issues]. Based on current clinical presentation, has this patient’s condition progressed from MCI to dementia? Please indicate:
|
For inpatient admissions where the patient has dementia and is admitted for behavioral management (agitation, psychosis, safety concern) — the behavioral disturbance should be captured with the appropriate 6th character. Additionally, if the admission is primarily for the behavioral complication of dementia, CDI should clarify whether the principal diagnosis should reflect the behavioral/neuropsychiatric symptom or the underlying dementia with behavioral disturbance — this affects MS-DRG assignment (MDC 19 Mental Diseases and Disorders vs. neurological DRGs).
🧑⚕️ Treatments (Clinical)
This section provides a clinical overview of dementia management to support CDI teams in understanding the therapeutic context behind documentation and care plans.
Pharmacological Management by Dementia Type
Alzheimer’s Disease
- Mild-to-moderate AD: Cholinesterase inhibitors (donepezil 5–10mg, rivastigmine 3–6mg BID or 4.6–9.5mg/24h patch, galantamine 8–24mg); clinical effect modest but statistically significant per Cochrane reviews
- Moderate-to-severe AD: Memantine 5–20mg added to AChEI (combination therapy); addresses NMDA excitotoxicity
- Early AD (MCI due to AD / mild AD dementia): Lecanemab (Leqembi) IV 10 mg/kg every 2 weeks initially, with maintenance options after 18 months per the current label; donanemab (Kisunla) IV every 4 weeks with titration of 350 mg, 700 mg, 1,050 mg, then 1,400 mg for infusion 4 and beyond; both require amyloid confirmation and ARIA monitoring with MRI per prescribing information
Vascular Dementia
No FDA-approved disease-specific pharmacotherapy. Management focuses on aggressive vascular risk factor reduction: antihypertensive therapy (target BP <130/80 per AHA/ACC guidelines), antiplatelet agents (aspirin, clopidogrel), statin therapy, glycemic control in diabetes. AChEIs have limited evidence for vascular dementia but are used off-label in mixed dementia (AD + vascular).
Dementia with Lewy Bodies
Rivastigmine is the most evidence-supported AChEI for DLB. Avoid antipsychotics (especially typical) — severe neuroleptic sensitivity reactions can be fatal in DLB. If antipsychotic is necessary, quetiapine at lowest effective dose with extreme caution. Treat REM sleep behavior disorder with clonazepam or melatonin.
Frontotemporal Dementia
No FDA-approved pharmacotherapy. AChEIs may worsen behavioral symptoms in FTD and are generally contraindicated. SSRIs (sertraline, fluvoxamine) used for disinhibition and compulsive behaviors; trazodone for agitation/insomnia; antipsychotics for severe behavioral symptoms.
Non-Pharmacological / Multidisciplinary Approaches
- Cognitive Rehabilitation: Compensatory strategies (memory aids, structured routines) for mild-to-moderate stages
- Occupational Therapy: ADL training, home safety assessment, adaptive equipment
- Speech-Language Pathology: Dysphagia management (common in advanced dementia), communication strategies
- Physical Therapy: Fall prevention, gait training, maintenance of mobility
- Caregiver Support Programs: Psychoeducation, respite care, support groups; reduces caregiver burden and delays nursing home placement
- Advance Care Planning: Early discussion of goals of care, POLST/MOLST, durable power of attorney for healthcare; particularly important given progressive nature of disease
Care Setting Considerations
Dementia management spans community (primary care, geriatric clinics), memory centers (specialized dementia care units), post-acute (SNF/NF for subacute rehabilitation or long-term care), and hospice settings. Each care setting has distinct coding, billing, and documentation requirements. Memory care units in residential settings may use specialized assessment tools (MDS for SNF RAI process) that generate coding data for ICD-10-CM assignment.
🎓 Patient Education / Summary
The following patient-oriented summary is designed to assist clinical documentation specialists and coders in understanding how patients and caregivers describe their conditions — and to help identify documentation opportunities from patient-reported history.
What Is Dementia?
Dementia is a general term for a group of symptoms affecting memory, thinking, behavior, and the ability to perform everyday activities. It is caused by damage to brain cells and is not a normal part of aging. According to the Alzheimer’s Association, approximately 55 million people worldwide live with dementia, and the condition is the 7th leading cause of death globally.
Common Questions Patients and Caregivers Ask
- “What type of dementia does my family member have?” — The answer (Alzheimer’s, vascular, Lewy body, etc.) is critical for code assignment. If the chart lacks a specific type, CDI should query.
- “How bad is the dementia right now?” — Severity (mild/moderate/severe) must be documented by the provider. Caregiver description of functional decline can support but not replace physician documentation.
- “Is the agitation/wandering/paranoia part of the dementia?” — Provider attribution of behavioral symptoms to the dementia is required to capture the behavioral disturbance 6th character. Nursing documentation of these symptoms alone does not support code assignment without physician acknowledgment.
- “Are there new treatments?” — For patients asking about lecanemab or donanemab, they must have early-stage Alzheimer’s with confirmed amyloid pathology. This is a CDI opportunity: confirm early AD diagnosis, mild severity code, and amyloid confirmation documentation.
Key Patient Education Points
- Dementia is a progressive condition; there is currently no cure, but treatments can slow symptoms or modify disease course
- Early diagnosis is important for access to treatments (anti-amyloid therapies for early AD) and care planning
- The National Institute on Aging provides free patient and caregiver education resources
- Safety planning (wandering, driving cessation, medication management, fall prevention) is a core component of dementia care
- Caregiver burden is a recognized clinical concern; caregivers should be screened and supported as part of comprehensive dementia care
- Advance care planning conversations should begin early, while the patient has decision-making capacity
Documentation Takeaway for CDI
From a clinical documentation standpoint, every dementia encounter is an opportunity to capture: (1) the specific underlying etiology, (2) the current severity, (3) any behavioral or neuropsychiatric manifestations, and (4) the active treatment plan. These four elements together ensure the most accurate ICD-10-CM code selection, support dementia severity tiering (V28 HCCs 125, 126, 127), and satisfy MEAT criteria for risk adjustment. When any element is missing from the documentation, a compliant CDI query is appropriate.
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2027 ICD-10-CM (effective October 1, 2026). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: October 2026 · Next scheduled review: October 2027 (FY2028 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
CCO Hero
Know someone starting a medical coding career?
Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.
Become a CCO Hero